Cargando…
Discovery of selective activators of PRC2 mutant EED-I363M
Many common disease-causing mutations result in loss-of-function (LOF) of the proteins in which they occur. LOF mutations have proven recalcitrant to pharmacologic intervention, presenting a challenge for the development of targeted therapeutics. Polycomb repressive complex 2 (PRC2), which contains...
Autores principales: | Suh, Junghyun L., Barnash, Kimberly D., Abramyan, Tigran M., Li, Fengling, The, Juliana, Engelberg, Isabelle A., Vedadi, Masoud, Brown, Peter J., Kireev, Dmitri B., Arrowsmith, Cheryl H., James, Lindsey I., Frye, Stephen V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484020/ https://www.ncbi.nlm.nih.gov/pubmed/31024026 http://dx.doi.org/10.1038/s41598-019-43005-z |
Ejemplares similares
-
Evaluation of EED Inhibitors as a Class of PRC2-Targeted
Small Molecules for HIV Latency Reversal
por: Turner, Anne-Marie W., et al.
Publicado: (2020) -
Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer
por: Chen, Huiming, et al.
Publicado: (2015) -
PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors
por: Lee, William, et al.
Publicado: (2014) -
The BAF and PRC2 Complex Subunits Dpf2 and Eed Antagonistically Converge on Tbx3 to Control ESC Differentiation
por: Zhang, Wensheng, et al.
Publicado: (2019) -
Maintenance of the functional integrity of mouse hematopoiesis by EED and promotion of leukemogenesis by EED haploinsufficiency
por: Ikeda, Kenichiro, et al.
Publicado: (2016)